Cytotoxic lymphocytes in the peripheral blood of patients with B cell lymphomas. 1995

Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
First Department of Internal Medicine, Tokyo Medical College, Japan.

In order to analyze systemic immune surveillance in patients with B cell non-Hodgkin's lymphomas (B-NHL), we investigated circulating lymphocytes using two-color flow cytometry. The proportions of CD3-CD56+ natural killer (NK) cells and CD8++(bright) S6F1++ killer-effector T cells corresponding to activated cytotoxic T lymphocytes (aCTL) were studied in the peripheral blood of 26 patients with indolent lymphoma (IL) and 24 with aggressive lymphoma (AL). The AL patients with both limited disease and advanced disease had an increased proportion of NK cells. However, this feature was not evident in IL patients with either limited or advanced disease. In contrast, an increased proportion of aCTL was observed only in IL patients with advanced disease. These findings indicate that IL may differ from AL in terms of immune surveillance against neoplastic B cells.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D016130 Immunophenotyping Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry. Lymphocyte Immunophenotyping,Lymphocyte Subtyping,Immunologic Subtyping,Immunologic Subtypings,Lymphocyte Phenotyping,Subtyping, Immunologic,Subtypings, Immunologic,Immunophenotyping, Lymphocyte,Immunophenotypings,Immunophenotypings, Lymphocyte,Lymphocyte Immunophenotypings,Lymphocyte Phenotypings,Lymphocyte Subtypings,Phenotyping, Lymphocyte,Phenotypings, Lymphocyte,Subtyping, Lymphocyte,Subtypings, Lymphocyte
D016393 Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. B-Cell Lymphoma,B Cell Lymphoma,B-Cell Lymphomas,Lymphoma, B Cell,Lymphomas, B-Cell

Related Publications

Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
November 2002, British journal of haematology,
Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
January 2005, Tsitologiia,
Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
August 1978, Clinical and experimental immunology,
Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
June 1974, British journal of haematology,
Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
January 1990, Current topics in microbiology and immunology,
Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
January 1978, Actas dermo-sifiliograficas,
Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
March 2004, Leukemia,
Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
July 1993, Cancer immunology, immunotherapy : CII,
Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
April 1990, Journal of immunology (Baltimore, Md. : 1950),
Y Kuriyama, and M Nakano, and Y Kawanishi, and O Iwase, and S Aizawa, and K Toyama
July 1994, Microscopy research and technique,
Copied contents to your clipboard!